Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether a blood pressure medication,
spironolactone, can be tolerated by older African American adults that have memory and
thinking problems, also called mild cognitive impairment (MCI). This study will also
investigate the effect of spironolactone on memory and thinking abilities as measured by
performance on cognitive tests, which are tests that measure memory and thinking skills.
Participants will take spironolactone or a placebo for one year and will have 4 to 5 study
visits during the study period.